The biotechnology company hVIVO announces that its client Cidara Therapeutics has entered into an agreement to be acquired by MSD for approximately $9.2 billion, following positive results from a Phase IIb trial of Cidara's influenza treatment candidate.
The contract research organization has secured over £5 million in new deals, including repeat business from German pharma clients, highlighting its expertise and growth potential.
The biotechnology company hVIVO has presented positive data from the development of new human challenge models for respiratory viruses, including hMPV, SARS-CoV-2 Omicron, and RSV B.
The healthcare company has received notification of a change in shareholding.
The healthcare company will be presenting at an upcoming industry conference.
The healthcare company has announced a change in its major shareholding.
The clinical research organization reported a significant decline in revenue and profitability for H1 2025, citing macroeconomic headwinds and sector-specific challenges impacting contract conversions and cancellations.
The healthcare company announces the release date for its interim results for the six months ended 30 June 2025.
The healthcare company has appointed a new Non-Executive Chair with extensive industry experience.
The healthcare company announces the proposed appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of due diligence.